Chemotherapy Resistance in Lung Cancer
- 15 December 2015
- book chapter
- Published by Springer Nature
- Vol. 893, 189-209
- https://doi.org/10.1007/978-3-319-24223-1_10
Abstract
Despite a growing interest in development of non-cytotoxic targeted agents, systemic chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, chemotherapy resistance limits our ability to effectively treat advanced lung cancer. Some lung tumors are intrinsically resistant to chemotherapy, and in virtually all cases, even the initial responders rapidly develop acquired resistance. While targeting histology could result in enhanced tumor sensitivity to a particular chemotherapeutic agent, better understanding of molecular determinants of chemotherapy sensitivity/resistance would be critically important. Development of predictive biomarkers to personalize chemotherapeutic agents and combining novel agents targeting specific resistance pathways with standard chemotherapy could be some promising strategies to overcome chemotherapy resistance in lung cancer. In this chapter, we will discuss some key mechanisms of resistance for commonly used chemotherapeutic agents in lung cancer.Keywords
This publication has 119 references indexed in Scilit:
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2013
- Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapyLung Cancer, 2011
- Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper ChelatorCancer Cell, 2010
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerCritical Reviews in Oncology/Hematology, 2010
- Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyLung Cancer, 2008
- The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate CarrierMolecular Pharmacology, 2008
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabineBritish Journal of Cancer, 2008
- ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell lineEuropean Journal Of Cancer, 1996